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Abstract 
Background:  The ATTRACT Trial previously reported that pharmacomechanical catheter-
directed thrombolysis (PCDT) did not prevent the post-thrombotic syndrome (PTS) in patients 
with acute proximal deep vein thrombosis (DVT). In the current analysis, we examine the effect 
of PCDT in ATTRACT patients with iliofemoral DVT.  
Methods: Within a large multicenter randomized trial, 391 patients with acute DVT involving 
the iliac and/or common femoral veins were randomized to PCDT with anticoagulation versus 
anticoagulation alone (No-PCDT) and were followed for 24 months to compare short-term and 
long-term outcomes.  
Results:  Between 6 and 24 months, there was no difference in the occurrence of PTS (Villalta 
scale >5 or ulcer: 49% PCDT versus 51% No-PCDT; risk ratio (RR)=0.95; 95% confidence 
interval (CI), 0.78–1.15; p=0.59).  PCDT led to reduced PTS severity as shown by: lower mean 
Villalta and Venous Clinical Severity Scores [VCSS] (p<0.01 for comparisons at 6, 12, 18, and 
24 months); and fewer patients with moderate-or-severe PTS (Villalta scale >10 or ulcer: 18% 
versus 28%; RR 0.65; 95% CI 0.45–0.94, p=0.021) or severe PTS (Villalta scale >15 or ulcer: 
8.7% versus 15%; RR 0.57; 95% CI 0.32-1.01, p=0.048; and VCSS >8: 6.6% versus 14%; RR 
0.46; 95% CI 0.24-0.87, p=0.013).  From baseline, PCDT led to greater reduction in leg pain and 
swelling (p<0.01 for comparisons at 10 and 30 days) and greater improvement in venous disease-
specific QOL (VEINES-QOL unit difference 5.6 through 24 months, p=0.029), but no difference 
in generic QOL (p > 0.2 for comparisons of SF-36 mental and physical component summary 
scores through 24 months).   In patients having PCDT versus No-PCDT, major bleeding within 
10 days occurred in 1.5% versus 0.5% (p=0.32), and recurrent VTE over 24 months was 
observed in 13% versus 9.2% (p=0.21). 
Conclusions:  In patients with acute iliofemoral DVT, PCDT did not influence the occurrence of 
PTS or recurrent VTE. However, PCDT significantly reduced early leg symptoms and, over 24 
months, reduced PTS severity scores, reduced the proportion of patients who developed 
moderate-or-severe PTS, and resulted in greater improvement in venous disease-specific QOL.  
Clinical Trial Registration: URL: www.clinicaltrials.gov Unique Identifier: NCT00790335 
Key Words:  deep vein thrombosis; iliofemoral; thrombolysis; post-thrombotic syndrome 
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Clinical Perspective  
 
What is new? 
• Outcomes are reported on a subgroup of 391 patients with acute iliofemoral DVT in 
whom pharmacomechanical catheter-directed thrombolysis (PCDT) was evaluated within 
a large multicenter randomized controlled trial (ATTRACT).  
• In patients with acute iliofemoral DVT, PCDT does not influence the occurrence of the 
post-thrombotic syndrome (PTS) or recurrent venous thromboembolism through 24 
months. 
• In patients with acute iliofemoral DVT, PCDT does appear to provide greater reduction 
in acute leg pain and swelling through 30 days follow-up, as well as reduced PTS 
severity, reduced moderate-or-severe PTS, and greater improvement in venous disease-
specific quality of life through 24 months. 
 
What are the clinical implications? 
• The findings support early use of PCDT in patients with acute iliofemoral DVT who have 
severe symptoms, low bleeding risk, and who attach greater importance to a reduction in 








Iliofemoral deep vein thrombosis (DVT), defined as DVT that involves the iliac and/or common 
femoral vein (with or without involvement of additional veins), often causes functional 
obstruction of venous outflow of the involved leg (1,2).  These patients are phenotypically 
distinct from patients with calf or femoral-popliteal DVT, based on more frequent recurrent 
venous thromboembolic events, more frequent post-thrombotic syndrome (PTS), and more 
severe PTS (1,3-7). Preliminary studies of catheter-directed thrombolysis and related methods 
have suggested that these strategies may be most useful in patients with iliofemoral DVT 
compared to those with less extensive proximal DVT, and that the occurrence and degree of 
thrombus clearance may correlate with clinical outcome (8-13).   
The biological plausibility that iliofemoral DVT should be recognized as a distinct entity 
in the anatomic spectrum of acute DVT is rooted in the anatomy and physiology of lower 
extremity venous return and the observation that venous recanalization occurs less often in 
patients with iliofemoral versus more distal DVT who were treated with anticoagulation alone or 
systemic thrombolysis (14,15).  As the entire volume of venous blood return is directed through 
the common femoral and iliac veins, obstruction of this channel results in marked post-
thrombotic venous hypertension (16) and severe post-thrombotic morbidity (3-7). 
 The main results of the Acute Venous Thrombosis: Thrombus Removal with Adjunctive 
Catheter-Directed Thrombolysis (ATTRACT) Trial, the largest randomized trial evaluating 
catheter based intervention for acute proximal DVT, were recently reported (17,18).  This study 
found no reduction of 2-year PTS frequency (the study’s primary outcome) or improvement in 
health-related quality of life (QOL) in patients treated with pharmacomechanical catheter-
directed thrombolysis (PCDT) compared with those treated with anticoagulation alone, although 
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there was a reduction in the severity of PTS in the PCDT-treated group.  Importantly, patients in 
this study were stratified by the most proximal extent of their DVT (iliofemoral versus femoral-
popliteal) prior to randomization, permitting a valid analysis of the outcomes of these two 
distinct anatomic-clinical presentations.  The purpose of this analysis is to report the benefits and 




The study design and the main study results for the overall ATTRACT cohort have been 
previously described (17,18).  In brief, this was a NIH-sponsored, Phase III, multicenter, 
randomized, open-label, assessor-blinded, parallel two-arm, controlled clinical trial 
(www.attract.wustl.edu; NCT00790335).  All patients provided written informed consent.  The 
study was approved by the Institutional Review Boards at all participating centers.  The authors 
and Steering Committee are solely responsible for the design and conduct of the study, all 
analyses, and the writing of this article.  The data and study materials will be made available to 
other researchers in accordance with the NIH Public Access Policy, at www.clinicaltrials.gov or 
by contacting the Corresponding Author.    
Patient Population, Stratification, and Randomization 
Patients presenting with DVT in the femoral or a more proximal vein with symptoms of 14 days 
or less were enrolled from 56 centers in the United States (U.S.).  Patients were stratified by 
clinical center and by the most proximal extent of their DVT, that is, whether the DVT involved 
the iliac and/or common femoral vein (“iliofemoral DVT”; this term applied whether or not more 
caudal veins were also involved), or not (“femoral-popliteal DVT”) (1,2). After stratification, 
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patients were randomized in a 1:1 ratio to receive either PCDT with anticoagulation (PCDT 
Arm), or anticoagulation alone (No-PCDT Arm), and followed for 2 years.  In this analysis, we 
report exclusively on the 391 patients with iliofemoral DVT; the patients with femoral-popliteal 
DVT are reported elsewhere. 
Treatments 
All patients were treated with initial and long-term anticoagulation consistent with published 
guidelines (19,20), and were provided knee-high 30 – 40 mm Hg ankle gradient elastic 
compression stockings (BSN Medical, Charlotte, NC) at their 10 day follow-up visit and every 6 
months.  
PCDT was performed as described elsewhere by board-certified physicians whose 
credentials were approved by the trial leadership, using methods consistent with published 
guidelines (21,22).  Recombinant tissue plasminogen activator (rt-PA) (alteplase, Activase®, 
Genentech, South San Francisco, CA) was infused into the thrombus using one of three methods: 
a standard multi-sidehole catheter ("infusion-first"); the AngioJet Rheolytic Thrombectomy 
System (Boston Scientific, Malborough, MA) (“power pulse-spray” or “rapid lysis” method); or 
the Trellis Peripheral Infusion System (Covidien, Inc., Mansfield, MA [now Medtronic], 
“isolated thrombolysis”).  Rt-PA dosing limits were: 1) 0.01 mg/kg/hr, not to exceed 1.0 mg/hr; 
2) no more than 30 hours infusion; 3) no more than 25 mg in any one procedure session; and 4) 
no more than 35 mg total.   After initial rt-PA delivery, physicians could use balloon maceration, 
catheter aspiration, thrombectomy devices, and/or balloon angioplasty to clear residual 
thrombus. Stent placement was encouraged for obstructive lesions in the iliac vein and/or 
common femoral vein causing > 50% diameter narrowing, > 2 mmHg mean pressure gradient, or 
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robust collateral filling on venography. Patients received heparin-based anticoagulation during 
PCDT, as previously described (17,18).   
Outcome Assessments 
Patient outcomes were assessed at 10 and 30 days, and at 6, 12, 18, and 24 months following 
randomization, by clinicians who were blinded to treatment allocation.  The adjudicators of 
safety and efficacy outcomes were also unaware of the treatment assignments. 
PTS, defined as a Villalta score of > 5 or a venous ulcer in the leg with the index DVT 
that occurred at any one or more assessments between the 6 month and 24 month follow-up visits 
(inclusive), was the study’s primary efficacy outcome (23,24).  The Villalta scale rates the 
severity of five patient-reported symptoms (pain, cramps, heaviness, pruritus, paresthesia) and 
six clinician-observed signs (edema, skin induration, hyperpigmentation, venous ectasia, 
redness), with each item scored from 0-3. Points for symptoms and signs are summed into a total 
score (range 0-33), and patients can be categorized as having no PTS (score 0-4), mild PTS 
(score 5-9), moderate PTS (score 10-14) or severe PTS (score >15, or presence of ulcer). 
Development of PTS was also attributed to patients if they underwent an unplanned 
endovascular procedure to treat severe venous symptoms beyond 6 months after randomization, 
unless there was a Villalta score < 5 in the previous 4 weeks. 
The severity of PTS was evaluated at 6, 12, 18, and 24 months using the Villalta score 
and the Venous Clinical Severity Score (VCSS) (25) as continuous measurements.  In addition, 
using the Villalta score, the presence of moderate or severe PTS (Villalta score ≥10, or an ulcer), 
or severe PTS (Villalta score ≥15, or an ulcer) were assessed as secondary outcomes. Using the 
VCSS (ranges from 0 to 27, with higher scores indicating more severe PTS), the presence of PTS 
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(VCSS score ≥4) and severe PTS (VCSS score ≥8) were also assessed using previously 
published criteria (26). 
Generic health-related quality of life (QOL) was assessed with the SF-36 Health Status 
Survey (27), and venous disease-specific QOL was assessed with the Venous Insufficiency 
Epidemiological and Economic Study Quality of Life (VEINES-QOL) measure (28).  
Leg pain and leg swelling were assessed at baseline, 10 days, and 30 days using a 7-point 
Likert pain scale and by measuring calf circumference (29). 
 Patients receiving PCDT had the amount of thrombus removal quantified by independent 
central readers using the proximal-vein components of the Marder score (30).   
 Safety outcomes included bleeding, recurrent venous thromboembolism, and death, 
which were recorded throughout follow-up and summarized through 10 days and 24 months.  
Clinically overt bleeding was classified as “major” if it was associated with a fall in the 
hemoglobin level of at least 2.0 g/dl, transfusion of ≥ 2 units of red blood cells, or involvement 
of a critical site (e.g., intracranial, intraspinal) (31). Less severe clinically overt bleeding was 
classified as “minor”. 
Sample Size 
Sample size for the entire ATTRACT study was 692 proximal DVT patients based on these 
assumptions: 30% of control patients would develop PTS between 6 and 24 months; PCDT 
would reduce PTS by at least 33%; 10% loss to follow-up; need to have 80% power to detect the 
hypothesized treatment effect; acceptance of a two-side α error of 0.05.  We did not estimate the 
sample size for the iliofemoral DVT subgroup, pre-specify the proportion of patients expected to 
have iliofemoral DVT, or require a minimum number of patients with iliofemoral DVT. A 
sample size of 391, corresponding to the number of patients in the current analysis, provides 
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approximately 80% power to detect (i) a 41% PTS reduction assuming a control proportion of 
30%, and (ii) an effect size (i.e. mean difference divided by the SD) of at least 0.28, assuming a 
two-sided α error of 0.05 with each type of analysis. 
Statistical Analysis 
Two types of analyses were performed: a modified intention-to-treat analysis (primary analysis) 
that included all randomized patients except those who did not have DVT at enrollment; and a 
per-protocol analysis (secondary analyses) that excluded patients who, within 7 days post-
randomization, were randomized to PCDT but did not receive it, or who were randomized to 
control but had skin puncture for PCDT thrombolysis or any thrombolytic therapy. 
Cumulative proportions were compared using the Cochran-Mantel-Haenszel test adjusted 
for clinical center. Treatment effects are summarized using stratum-adjusted risk ratios (RR) 
with their corresponding 95% confidence intervals (CI).   
The mean Villalta,VCSS, and QOL assessments at each visit were estimated using piece-
wise linear regression growth curve models adjusting for clinical center and pre-specified 
baseline covariates (age, sex, body-mass index, race). Changes from baseline to 10 days and 
from baseline to 30 days for leg pain scores and calf circumferences in the index leg were 
compared using multiple linear regression, adjusted for clinical center. A supportive analysis 
modeled the values at 10 days and 30 days with the baseline value as a covariate. For the binary 
outcomes, interaction tests for subgroups were conducted using a logistic model with treatment, 
subgroup, and an interaction term as factors, with interaction p-values calculated using Wald 
joint tests.  The risk ratios and 99% confidence intervals derived from the models were used to 
create the forest plots.  
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The analyses in this report are considered exploratory because, although they were pre-
specified, they are confined to a subgroup of the main trial. 
 
Results  
Baseline Characteristics of Participants 
Of the 692 patients in ATTRACT, 391 (57%) had iliofemoral DVT of whom 196 were 
randomized to PCDT and 195 were randomized to No-PCDT (Figure 1). Median age was 52 
years, 53% were male, the index DVT was in the left leg in 64%, and symptoms were present for 
a median of 6 days (Table 1). Baseline characteristics were well balanced between the two 
treatment groups (Table 1) 
Protocol and Treatment Adherence 
Within 7 days after randomization, 4 patients assigned to No-PCDT had PCDT, and 6 patients 
assigned to PCDT did not have the procedure (Figure 1).  These patients were excluded from the 
per-protocol analysis.  PCDT was performed at a median one day post-randomization.  Initial 
anticoagulant therapy, which was usually low molecular weight heparin or unfractionated 
heparin, was similar in the PCDT and No-PCDT patients (Table 2). The initial rt-PA delivery 
method in PCDT Arm patients was the "infusion first" method in 52% (median total rt-PA dose 
of 21 mg), the AngioJet method in 24% (median total rt-PA dose of 21 mg), and the Trellis 
method in 19% (median total rt-PA dose of 20 mg) (PCDT not performed in 5%; Table 2). After 
initial rt-PA delivery, additional endovascular methods were used in 91% of patients, as 
summarized in Table 2. Mean thrombus removal as assessed by pre and post PCDT venography 
was 86% (mean pre-procedure and post-procedure Marder scores 12.0 and 3.0, respectively, 
change -9.1; 95% CI, -8.2 to -10.0; p <0.001).   The mean duration of anticoagulation before first 
11 
permanent cessation during follow-up, use of antiplatelet therapy, and use of compression 
stockings were similar in the PCDT and No-PCDT patients (Table 2).   
Development of Post-Thrombotic Syndrome 
In the intention-to-treat analysis using the study’s primary outcome measure (Villalta scale), PTS 
developed in 96 of 196 (49%) PCDT Arm patients and in 100 of 195 (51%) No-PCDT Arm 
patients (RR=0.95; 95% CI, 0.78-1.15; p=0.59) during 24 months follow-up (Table 3).  In the 
per-protocol analysis and in all subgroups evaluated, the findings were similar (Figure 2, 
Supplemental Table 1).  Using the VCSS scale, PTS developed in 30% of PCDT Arm patients 
and in 40% of No-PCDT Arm patients (RR=0.75; 95% CI, 0.57-0.98; p=0.034) (Table 3).  In the 
per-protocol analysis, these findings were similar (29% PCDT versus 41% No-PCDT, RR=0.71, 
95% CI, 0.54-0.94, p=0.015) (Supplemental Table 1). 
Severity of Post-Thrombotic Syndrome 
At 6, 12, 18, and 24 months, mean Villalta and VCSS scores were significantly lower in the 
PCDT Arm compared with the No-PCDT Arm (p< 0.01 at all time-points, both analysis sets) 
(Table 4, Figure 3) (32). 
Moderate-or-severe PTS, as assessed by a Villalta scale score ≥10 or ulceration, 
developed in 36 (18%) patients assigned to PCDT and in 55 (28%) patients assigned to No-
PCDT (RR=0.65; 95% CI, 0.45 to 0.94; p=0.021) (Table 3). The findings were similar in a per-
protocol analysis (RR=0.63, p=0.013) (Supplemental Table 1).  For this outcome, patients’ sex, 
race, symptom duration (0-1 versus 1-2 weeks), side of DVT, and baseline symptom severity did 
not influence the effect of PCDT.  However, patients < 65 versus ≥ 65 years old (p-
interaction=0.04) and those with versus without a major reversible DVT risk factor at diagnosis 
12 
(p-interaction=0.05) appeared less likely to develop moderate-or-severe PTS with use of PCDT 
(Figure 4).   
 Severe PTS, as assessed by a Villalta score ≥15 or ulceration, developed in 17 (8.7%) 
patients assigned to PCDT and in 30 (15%) patients assigned to No-PCDT (RR=0.57; 95% CI, 
0.32 to 1.01; p=0.048) (Table 3).  Severe PTS, as assessed by a VCSS score > 8, developed in 13 
(6.6%) patients assigned to PCDT and 28 (14%) patients assigned to No-PCDT (RR=0.46; 95% 
CI, 0.24 to 0.87; p=0.013) (Table 3).  These findings were similar in per-protocol analyses 
(Supplemental Table 1).  Ulceration developed in 9 (4.6%) patients assigned to PCDT and in 12 
(6.2%) patients assigned to No-PCDT (RR=0.75; 95% CI, 0.32 to 1.73, p=0.49).   
Change in Presenting Symptoms and Health-Related Quality of Life 
Mean change in leg pain from baseline for PCDT versus No PCDT was -1.76 versus -1.25 Likert 
points at 10 days (p=0.009), and -2.36 versus -1.80 Likert points at 30 days (p=0.008) (Table 4).  
Mean change in calf circumference from baseline for PCDT versus No PCDT was -0.79 cm 
versus +0.22 cm at 10 days (p=0.002) and -1.37 cm versus -0.10 cm at 30 days (p<0.001).  The 
findings for these outcomes were similar in the per-protocol analyses (Supplemental Table 2). 
Mean change in venous disease-specific quality of life from baseline to 24 months was 
28.6 versus 23.0 VEINES-QOL scale units in the PCDT versus No-PCDT Arms (between-group 
difference 5.6 units, p=0.029). In the per-protocol analysis, this between-group difference was 
5.3 units (p=0.04). 
Mean change in the symptoms component of venous disease-specific quality of life from 
baseline to 24 months was 21.5 versus 16.2 VEINES-Sym scale units in the PCDT versus No-
PCDT Arms (between-group difference 5.2 points, p=0.043).  In the per-protocol analysis, this 
between-group difference was 5.1 units, p=0.012). 
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Mean change in generic quality of life (physical and mental component summary scores 
of SF-36 measure) from baseline to 24 months did not differ for the PCDT versus No-PCDT 
patients in either the intention-to-treat or per-protocol analyses (p>0.25 for all analyses, Table 4, 
Supplemental Table 2).   
Safety Outcomes 
Within 10 days, in PCDT versus No-PCDT patients, major bleeding occurred in three patients 
(1.5%) versus one patient (0.5%) (p=0.32), and any bleeding occurred in seven (3.6%) versus 
four (2.1%) patients (p=0.36) (Table 3). There were no fatal or intracranial bleeds. Recurrent 
venous thromboembolism within 24 months occurred in 26 (13.3%) PCDT versus 18 (9.2%) No-
PCDT patients (p=0.21) (none were fatal). Of the six deaths in each group, none occurred within 
10 days post-randomization (Table 3).  Per-protocol analyses of the safety outcomes were 
similar (Supplemental Table 1). 
 
Discussion 
Contemporary clinical practice guidelines (including a Scientific Statement from the American 
Heart Association) recommend that studies of DVT therapy report outcomes separately for 
patients with iliofemoral versus less extensive DVT (1,2). These and other guidelines (19,20,22) 
also identify thrombus extent as a key factor to consider when deciding which patients should 
receive endovascular thrombus removal, which accounts for why some randomized trials have 
evaluated endovascular DVT therapies exclusively in patients with iliofemoral DVT (33-35).  
Consequently, this report focuses on findings in the iliofemoral DVT subgroup of the ATTRACT 
study. 
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Several studies have described favorable outcomes for aggressive thrombus removal 
therapies in comparison to anticoagulation alone in iliofemoral DVT, but each had major 
methodological limitations that undermine confidence in their findings.  A small randomized 
trial evaluating surgical venous thrombectomy for acute iliofemoral DVT versus anticoagulation 
alone reported improved long term iliofemoral patency and reduced post-thrombotic morbidity in 
the surgically-treated patients (36).  A post-hoc analysis of data from a prospective multicenter 
registry found that 68 CDT-treated patients had significantly fewer PTS symptoms, better 
physical functioning, less stigmata of chronic venous insufficiency, and less health distress 
(p<0.05 for all outcomes) at a mean follow-up of 16 months compared with 30 retrospectively 
“matched” patients who were treated with anticoagulation alone (9).  A prospective non-
randomized study (n=51) found better 6-month and 5-year venous patency and freedom from 
venous symptoms in patients who received CDT versus anticoagulation alone (37).  Finally, a 
single-center randomized trial comparing streptokinase CDT versus anticoagulation alone 
observed a higher rate of normal venous function and less valvular reflux in CDT recipients (38). 
However, these studies were limited by potential selection bias and baseline differences between 
treatment groups due to their non-randomized design (9,37), small sample size (9,36-38), 
performance in a single center (37,38), and lack of rigorous PTS assessment with validated tools 
(38).   
A recent multicenter randomized trial that evaluated CDT for proximal DVT above mid-
thigh level (the CAVENT Trial) found that CDT reduced PTS, which significantly correlated 
with patency of the ipsilateral iliofemoral venous segment (11,13). Since CAVENT did not 
report outcomes separately for iliofemoral DVT and femoral-popliteal DVT patients, we are 
unable to combine data from the iliofemoral subgroups of the two trials.  Although in the total 
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study population, CAVENT reported that CDT reduced any PTS, CDT did not improve long-
term QOL and was associated with major and non-major bleeding complications. Consequently, 
we suggest that the findings of ATTRACT and CAVENT collective argue against routine first-
line thrombolysis for proximal DVT, but that patients with iliofemoral DVT or more severe 
presentations may derive benefit and deserve further examination.  
This exploratory analysis of the iliofemoral DVT subgroup in the ATTRACT Trial did 
not find an effect of PCDT upon the development of “any PTS” over 2 years using the pre-
specified primary trial outcome (Villalta score threshold of 5), and did not find an effect upon 
bleeding.  These findings were similar in the per-protocol analysis, and they are consistent with 
PCDT treatment effects for “any PTS” in the iliofemoral and femoral-popliteal subgroups that 
did not differ significantly (p-interaction=0.85) (18). Although PCDT reduced the occurrence of 
PTS in a pre-specified secondary assessment using the VCSS, we chose the Villalta scale as the 
trial’s primary outcome measure based upon a more extensive body of literature and 
international societal recommendations supporting its use to detect incident PTS, including more 
rigorous assessment of the Villalta threshold score than the VCSS threshold score (23-26).  
Additional studies to compare the performance characteristics of these two PTS scales, using the 
ATTRACT and other datasets, would be worthwhile.  
 The data from this analysis collectively suggest that PCDT improves short-term recovery 
from DVT and reduces long-term progression of PTS severity in patients with iliofemoral DVT. 
Evidence favoring PCDT includes:  1) greater reduction in leg pain and swelling through 30 days 
(p<0.01); 2) reduced PTS severity (p<0.01 for Villalta and VCSS comparisons) at 6, 12, 18, and 
24 months; 3) reduced occurrence of moderate-or-severe PTS (p=0.021 for comparison of 
proportion with Villalta > 10) and severe PTS (p<0.05 for comparisons of proportions with 
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Villalta > 15 and VCSS > 8) through 24 months; and 4) greater improvement in venous disease-
specific QOL from baseline to 24 months (5.6 points on VEINES-QOL scale, p=0.029).  These 
findings were consistent in the per-protocol analyses. 
However, the findings of this analysis should not be considered conclusive evidence that 
PCDT reduces the occurrence of moderate-or-severe PTS in patients with iliofemoral DVT.  
Moderate-or-severe PTS was one of a number of secondary outcomes. Although assessors were 
blinded to treatment arm, healthcare providers and patients were not blinded. Hence, further 
studies are recommended to determine whether PCDT truly reduces moderate-or-severe PTS in 
patients with iliofemoral DVT. 
In this analysis, there was a suggestion that PCDT exerted a more positive effect upon the 
moderate-or-severe PTS outcome in iliofemoral DVT patients who were < 65 years of age versus 
those > 65 years old (p-interaction = 0.04), and upon patients whose DVT was provoked by a 
major reversible risk factor (p-interaction = 0.05).  However, as these two results are in 
subgroups within the iliofemoral subgroup, and as they are among many outcomes that were 
evaluated in the study, and as the tests of interaction were not strongly positive, these two 
findings may have occurred by chance (39,40). 
 Our analysis has several limitations. First, there was substantial loss to follow-up that 
was unbalanced between the treatment groups (more missed PTS assessments in the No-PCDT 
Arm), which influenced the study’s estimates of treatment effects (18). As only 57% of 
ATTRACT Trial patients had iliofemoral DVT, power to detect differences in outcomes with 
PCDT versus No-PCDT in the iliofemoral DVT subgroup is substantially less than in the overall 
trial.  Furthermore, in the absence of a statistically significant test of interaction to support a 
difference in the PCDT treatment effect upon moderate-or-severe PTS between the iliofemoral 
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and femoral-popliteal subgroups, the treatment effect estimate from the overall trial may be the 
most reliable estimate of the treatment effect in each of these two subgroups (39,40).  This is also 
true for the assessment of bleeding, which was statistically higher  with use of PCDT in the 
overall ATTRACT Trial.  On the other hand, tests of interaction to detect differences in 
treatment effects between subgroups have low power in a medium-sized study such as 
ATTRACT. Strengths of this analysis include that it was pre-specified; that the presence of 
iliofemoral DVT was a stratification variable that was identified prior to randomization; and that 
the reduction in PTS severity with PCDT was a consistent finding across multiple venous 
outcome measures.   We excluded patients with either asymptomatic DVT or DVT causing acute 
circulatory compromise since they could not be ethically randomized to one or the other 
treatment strategy, and we acknowledge that a) the enrolled patients had varying baseline 
symptom severity (and perhaps PTS risk); b) patients with recurrent ipsilateral DVT within the 
last 2 years (who are expected to have a high risk of PTS) were excluded; and c) site 
investigators could have chosen to bypass the study for selected patients at either end of the 
severity spectrum.  However, throughout the study we provided detailed education to study 
centers that explicitly addressed this issue and strongly encouraged the enrollment of all willing 
iliofemoral DVT patients who met the study eligibility criteria. This analysis is also the largest 
report of randomized trial outcomes specifically in patients with iliofemoral DVT. 
In conclusion, the findings of this exploratory analysis strongly suggest that PCDT 
reduces acute leg pain and swelling, reduces PTS severity, and improves venous QOL in patients 
with acute iliofemoral DVT. These findings support early use of PCDT in patients with acute 
iliofemoral DVT who have severe symptoms, low bleeding risk, and who attach greater 
importance to a reduction in early and late symptoms than to the risks, cost, and inconvenience 
18 
of PCDT.  A decision to use PCDT should factor in this study’s limitations (including the lack of 
patient blinding) and should be made only after a careful review of the bleeding risk in that 
individual patient. Further prospective study of PCDT and other endovascular therapies should 
be targeted to the subset of patients with iliofemoral DVT. 
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Table 1.  Baseline Characteristics by Treatment Group 
 
Baseline Characteristic 
PCDT No PCDT Total 
n = 196 n = 195 N = 391 
Age, years: median (IQR)  51 (39, 62) 52 (42, 61) 52 (39, 62) 
Male: n (%) 107 (55) 101 (52) 208 (53) 
Race: n (%)    
White 158 (81) 148 (76) 306 (78) 
Black/African-American 33 (17) 35 (18) 68 (17) 
Other 5 (3) 12 (6) 17 (4) 
Body mass index, kg/m2: median (IQR) 31 (28, 37) 31 (26, 36) 31 (27, 37) 
Symptom severity (Villalta*) class: n (%)†    
None or minimal (score 0-4) 24 (12) 31 (16) 55 (14) 
Mild (score 5-9) 65 (33) 65 (33) 130 (33) 
Moderate (score 10-14) 60 (31) 56 (29) 116 (30) 
Severe (score ≥ 15) 47 (24) 42 (22) 89 (23) 
Leg with index DVT, Left: n (%) 124 (63) 125 (64) 249 (64) 
Previous DVT or PE: n (%) 48 (24) 45 (23) 93 (24) 
Previous ipsilateral DVT: n (%) 3 (2) 10 (5) 13 (3) 
DVT risk factors: n (%)‡    
Major surgery 19 (10) 21 (11) 40 (10) 
Hospitalization 17 (9) 29 (15) 46 (12) 
Plaster cast immobilization 7 (4) 3 (2) 10 (3) 
Childbirth 3 (2) 5 (3) 8 (2) 
Outpatient: n (%) 156 (80) 156 (80) 312 (80) 
Days from start of DVT symptoms to rand: median 
(IQR) 
6 (3, 9)  6 (3, 9)  6     (3, 9) 
eGFR, mL/min: median (IQR) 84 (67, 103)  88 (72, 104)  86     (70, 103) 
Leg pain severity: n (%)    
0-2 34 (17) 43 (22) 77 (20) 
3-4 60 (31) 59 (30) 119 (30) 
5-7 99 (51) 91 (47) 190 (49) 
Unknown 3 (2) 2 (1) 5 (1) 
Between-leg circumference difference§, cm: 
median (IQR) 
 3 (2, 5)   3    (2, 4) 3        (2, 5) 
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Baseline Characteristic 
PCDT No PCDT Total 
n = 196 n = 195 N = 391 
Pre-randomization ACǁ therapy: n (%)‡ 180 (92) 184 (94) 364 (93) 
LMWH  101 (56) 110 (60) 211 (58) 
UFH 61 (34) 60 (33) 121 (33) 
Rivaroxaban 7 (4) 7 (4) 14 (4) 
Warfarin 89 (49) 98 (53) 187 (51) 
Other 11 (6) 7 (4) 18 (5) 
* Villalta Scale: 5 patient-reported signs (cramps, itching, pins & needles, leg heaviness, pain) and 6 
blinded clinician-reported symptoms (pretibial edema, skin induration, hyperpigmentation, venous 
ectasia, redness, pain during calf compression) scored on a 4-point scale (0=none/minimal, 1=mild, 
2=moderate, 3=severe) and summed into a total score, or the presence of an ulcer (score=15), for the 
leg with index DVT 
† One patient in the No PCDT was not assessed 
‡ Subjects may fit into more than one category 
§ Leg circumference with index DVT minus Leg circumference of the other leg 
ǁ Anticoagulant (AC) therapy that was given after DVT diagnosis and before randomization 
IQR, inter-quartile range; DVT, deep vein thrombosis; PE, pulmonary embolism; rand, randomization; 
eGFR, estimated glomerular filtration rate; LMWH, low molecular weight heparin; UFH, 
unfractionated heparin  
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Table 2.  Study Treatments Post Randomization 
 
Treatment over Time 
PCDT 
n = 196 
No PCDT 
n = 195 
Initial AC* therapy: n (%)† n = 194 n = 193 
UFH 73 (38) 42 (22) 
LMWH 99 (51) 132 (68) 
Other  29 (15) 28 (15) 
At 30 days: n (%)† n = 183 n = 173 
Any AC Therapy 177 (97) 167 (97) 
Antiplatelet Therapy 30 (16) 26 (15) 
Compression stockings used ≥ 3 days per week 135 (74) 136 (79) 
At 6 months: n (%)† n = 169 n = 150 
Any AC Therapy 136 (80) 126 (84) 
Antiplatelet Therapy 34 (20) 23 (15) 
Compression stockings used ≥ 3 days per week 111 (66) 108 (72) 
At 24 months: n (%)† n = 141 n = 131 
Any AC Therapy 66 (47) 68 (52) 
Antiplatelet Therapy 44 (31) 39 (30) 
Compression stockings used ≥ 3 days per week 77 (55) 74 (56) 
Duration of AC therapy: n (%)   
Never started 2 (1) 2 (1) 
Not stopped during study period 106 (54) 108 (55) 
Stopped during study period:  88 (45) 85 (44) 
Days to stopping: median (IQR)  213 (182, 367)  270 (182, 395) 
PCDT Procedure Details (PCDT Arm only) 
Initial rt-PA delivery method:   
Infusion-First: n (%) 102 (52)  
rt-PA total dose, mg: median (IQR) 21 (18, 26)  
rt-PA duration, hours: % below 4h, mean (SD)‡ 0%,23 (7.2)  
AngioJet: n (%) 46 (24)  
rt-PA total dose, mg: median (IQR) 21 (15, 28)  
rt-PA duration, hours: % below 4h, mean (SD)‡ 46%, 20 (5.5)  
Trellis: n (%) 38 (19)  
rt-PA total dose, mg: median (IQR) 20 (12, 30)  
rt-PA duration, hours: % below 4h, mean (SD)‡ 58%, 20(4.6)  
Other§: n (%) 10 (5)  
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Treatment over Time 
PCDT 
n = 196 
No PCDT 
n = 195 
Additional endovascular methods used: n (%)   
None  18 (9)  
1 or more 178 (91)  
Type of additional method: n (%)†   
Balloon venoplasty 128 (72)  
Balloon maceration 105 (59)  
Rheolytic thrombectomy (AngioJet) 104 (58)  
Stent placement 70 (39)  
Large-bore catheter aspiration 44 (25)  
Isolated thrombolysis (Trellis) 11 (6)  
Veins that were accessed: n (%)† 192 (98)  
Ipsilateral Popliteal Vein 172 (90)  
Ipsilateral Tibial Vein 12 (6)  
Ipsilateral Common Femoral Vein 5 (3)  
Internal Jugular Vein 12 (6)  
Other Vein 17 (9)  
Marder scores: median (IQR)   
Pre-lysis (n=180) 11 (8, 16)  
Post-lysis  (n=178) 2  (0,   4)  
Pre-post Decrease (n=176) 9 (4, 13)  
*Anticoagulation (AC) therapy given post randomization 
† Subjects may fit into more than one category 
‡ Distributions are bimodal with spikes below 4 hours (means and SDs are for post 4-hour data)  
§ 6 PCDT procedures where there was no acute thrombus on venogram and 4 not attempted 
IQR, Inter-quartile range; rt-PA, recombinant tissue plasminogen activator; SD, standard deviation 
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n = 196 
No PCDT 
n = 195 
Risk Ratio 
P Value 
Events (%) Events (%) Estimate 95% CI 
PTS*:         
Ulcer (any assessment) 9 (4.6%) 12 (6.2%)    
Villalta ≥ 5 (without ulcer) 86 (44%) 88 (45%)    
Late endovascular procedure only 1 (0.5%) 0 (0%)    
Total 96 (49%) 100 (51%) 0.95* 0.78, 1.15 0.59 
PTS: VCSS ≥ 4* 59 (30%) 78 (40%) 0.75* 0.57, 0.98 0.034 
PTS incidence proportion: †        
At 6 months 50/169 (30%) 68/149 (46%) 0.65 0.48, 0.87  
At 12 months 58/155 (37%) 49/137 (36%) 1.05 0.77, 1.42  
At 18 months 46/139 (33%) 47/123 (38%) 0.87 0.63, 1.20  
At 24 months 48/145 (33%) 52/133 (39%) 0.85 0.62, 1.16  
Moderate-severe PTS (Villalta ≥ 10) ‡ 36 (18%) 55 (28%) 0.65* 0.45, 0.94 0.021 
Moderate-severe PTS incidence 
proportion: § 
       
At 6 months 19/169 (11%) 29/149 (19%) 0.58 0.34, 0.99  
At 12 months 18/155 (12%) 24/137 (18%) 0.66 0.38, 1.17  
At 18 months 16/139 (12%) 23/123 (19%) 0.62 0.34, 1.11  
At 24 months 17/145 (12%) 25/133 (19%) 0.62 0.35, 1.10  
Severe PTS: Villalta ≥ 15 ǁ 17 (8.7%) 30 (15%) 0.57* 0.32, 1.01 0.048 
Severe PTS: VCSS ≥ 8  ǁ 13 (6.6%) 28 (14%) 0.46* 0.24, 0.87 0.013 
Major non-PTS treatment failure 4 (2.0%) 5 (2.6%) 0.80 0.22, 2.92 0.73 
Any treatment failure ** 97 (49%) 103 (53%) 0.93* 0.77, 1.13 0.47 
Major bleeding in first 10 days 3 (1.5%) 1 (0.5%) 2.98 0.31, 28.4 0.32 
Any bleeding in first 10 days 7 (3.6%) 4 (2.1%) 1.74 0.52, 5.85 0.36 
VTE:        
First 30 days 11 (5.8%) 6 (3.1%) 1.82 0.69, 4.83 0.22 
Total over 24 months 26 (13%) 18 (9.2%) 1.44 0.81, 2.53 0.21 
Death  6 (3.1%) 6 (3.1%) 0.99 0.33, 3.03 0.99 
* Cochran-Mantel-Haenszel (CMH) test adjusted for center, cumulative proportion of patients who developed PTS at any 
time between 6-24 months, inclusive. Villalta scores (0-33 range); VCSS scores (0-27 range), higher is worse for both.   
† At each visit, the proportion of patients with any PTS according to the Villalta scale among those who had an assessment 
performed (denominator) 
‡ Cumulative proportion with moderate or severe PTS (pre-specified analysis)  
§ At each visit, the proportion of patients with moderate or severe PTS according to the Villalta scale among those who had 
an assessment performed (denominator)  
ǁ Cumulative proportion with severe PTS  ** Composite of PTS or major non-PTS treatment failure. 
PTS, post-thrombotic syndrome; CI, confidence interval; VTE, venous thromboembolism
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Table 4.  Continuous Study Outcomes by Treatment Group (Intention-to-Treat Analysis) 
* Mean scores, standard errors (SE) and treatment differences estimated using growth curve models and piece-
wise linear regression adjusted for center, and baseline covariates (age, sex, BMI, race) 
†Villalta scores (0-33 range) – higher is worse  
‡ Mean scores, standard errors (SE) and treatment differences estimated using growth curve models and piece-
wise linear regression adjusted for center, and baseline covariates (age, sex, BMI, race, Villalta score) 
§ VCSS scores (0-27 range) – higher is worse  
ǁ Model estimates are unchanged from month 6 to month 12 due to the lack of a significant time trend 
** SF-36 major scales: physical component score (PCS, 0-100 range) and mental component score (MCS, 0-100 
range) – higher is better, with a difference of 3 to 4 points considered clinically meaningful; †† VEINES overall 
score (0-100 range) and symptom specific score (0-100 range) – higher is better; ‡‡ Mean change scores, SEs, and 
treatment differences estimated using multiple linear regression adjusted for center; §§ patient-reported severity of 
pain in the index leg (0-7 range) – higher is worse; ǁǁ leg circumference measured at 10cm below tibial tuberosity 






n = 196 
No PCDT 
n = 195 
PCDT – No PCDT 
Difference 
n mean (SE) n mean (SE) Estimate (SE) P-value 
Villalta mean scores*†:       
At 6 months 169 3.70 (0.51) 149 5.38 (0.50) -1.68 (0.47) <0.001 
At 12 months 155 3.78 (0.50) 137 5.43 (0.49) -1.65 (0.45) <0.001 
At 18 months 139 3.86 (0.52) 123 5.49 (0.50) -1.62 (0.48) <0.001 
At 24 months 145 3.95 (0.54) 133  5.54 (0.54) -1.60 (0.54) 0.0033 
VCSS mean scores‡§:       
At 6 months 168 1.82 (0.32) 145 2.98 (0.32) -1.16 (0.28) <0.001 
At 12 months 151 ǁ 134 ǁ ǁ ǁ 
At 18 months 135 1.67 (0.35) 121 3.43 (0.35) -1.76 (0.34) <0.001 
At 24 months 132 1.98 (0.35) 122  2.80 (0.35) -0.82 (0.34) 0.018 
SF-36 general Quality of Life‡: **       
PCS: Change, baseline to 24 months 141 10.65 (0.95) 128 11.43 (0.99) -0.78 (1.17) 0.51 
MCS: Change, baseline to 24 months 141 2.85 (0.82) 128 4.02 (0.86) -1.17 (1.09) 0.28 
VEINES disease-specific Quality of Life‡: ††       
Overall: Change, baseline to 24 months 141 28.63 (1.97) 128 23.02 (2.07) 5.61 (2.6) 0.029 
Symptoms: Change, baseline to 24 months 140 21.45 (1.96) 128 16.24 (2.06) 5.21 (2.56) 0.043 
Leg pain severity‡‡ (7-point scale): §§       
Change, baseline to Day 10 181 -1.76 (0.14) 177 -1.25 (0.14) -0.51 (0.19) 0.0093 
Change, baseline to Day 30 178 -2.36 (0.15) 171 -1.80 (0.15) -0.56 (0.21) 0.0082 
Index leg circumference‡‡ (cm): ǁǁ       
Change, baseline to Day 10 175 -0.79 (0.23) 177 0.22 (0.23) -1.00 (0.32) 0.0019 
Change, baseline to Day 30 174 -1.37 (0.22) 170 -0.10 (0.23) -1.27 (0.32) <0.001 
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Figure Legends  
 
Figure 1. Patient flow diagram for the iliofemoral DVT subgroup in the ATTRACT trial.  
PCDT, pharmacomechanical catheter-directed thrombolysis; DVT, deep-vein thrombosis; LEP, 
Late Endovascular Procedure (not including inferior vena cava filter). 
 
Figure 2. Subgroup analysis of PTS in patients with iliofemoral DVT.  
Forest plot of risk ratios (PCDT versus No PCDT) for the occurrence of PTS from 6 to 24 
months among subgroups of patients. The horizontal lines represent 99% confidence intervals. 
PCDT, pharmacomechanical catheter-directed thrombolysis; DVT, deep vein thrombosis. 
 
Figure 3: LOESS* of raw and predicted mean Villalta scores by treatment group 
Graphical display (locally weighted scatterplot smoothing) of the Villalta Scores evaluating PTS 
severity by treatment arm, derived from piecewise-linear growth-curve models of the repeated 
assessments from baseline through 24 months. 
 
Figure 4. Subgroup analysis of moderate-or-severe PTS in patients with iliofemoral DVT.  
Forest plot of risk ratios (PCDT versus No PCDT) for the occurrence of moderate-or-severe PTS 
from 6 to 24 months among subgroups of patients. The horizontal lines represent 99% 
confidence intervals. 
PCDT, pharmacomechanical catheter-directed thrombolysis; DVT, deep vein thrombosis. 
 
 Patients with Iliofemoral DVT 
n = 391 
No PCDT 
n = 195 
 
n = 608 
Received PCDT in first 7 days (n=4) 
LEP done during 24 months (n=9) 
Treatment 
Completed 24 months (n=135) 
Follow-up <24 months (n=60): 
- Death (n=6) 
- Withdrew consent (n=16) 
- Lost to follow-up (n=38) 
1.1  
Follow-up 
 n = 195 (modified ITT) 
n = 191 (per-protocol) 
Analyzed 
Completed 4 assessments (n=110) 
Completed 1-3 assessments (n=54) 





n = 196  
Did not get PCDT in first 7 days (n=6) 
LEP done during 24 months (n=12) 
Completed 24 months (n=145) 
Follow-up <24 months (n=51): 
- Death (n=5) 
- Withdrew consent (n=9) 
- Lost to follow-up (n=37) 
 n = 196 (modified ITT) 
n = 190 (per-protocol) 
Completed 4 assessments (n=120) 
Completed 1-3 assessments (n=58) 
Missed all 4 assessments (n=18) 





Leg symptom  
duration 
Side of DVT 















< 1 week 












< 3 cm 
≥ 3 cm 
PCDT vs No PCDT 
71/157 vs 84/164 
25/39 vs 16/31 
42/89 vs 41/94 
54/107 vs 59/101 
15/33 vs 21/35 
78/158 vs 74/148 
59/128 vs 62/121 
37/68 vs 38/74 
58/124 vs 65/125 
38/72 vs 35/70 
14/29 vs 21/38 
82/167 vs 79/157 
7/24 vs 10/31 
35/65 vs 28/65 
27/60 vs 31/56 
27/47 vs 31/42 
15/34 vs 17/43 
32/60 vs 28/59 
48/99 vs 54/91 
37/68 vs 33/71 











0.25 0.50 1.0 2.0 4.0 
Risk Ratio (99% CI) 
Favors PCDT 
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Side of DVT 
Major risk factor 
Villalta severity score 











< 1 week 












< 3 cm 
≥ 3 cm 
PCDT vs No PCDT 
25/157 vs 49/164 
11/39 vs 6/31 
16/89 vs 23/94 
20/107 vs 32/101 
8/33 vs 12/35 
27/158 vs 39/148 
21/128 vs 35/121 
15/68 vs 20/74 
22/124 vs 39/125 
14/72 vs 16/70 
3/29 vs 15/38 
33/167 vs 40/157 
2/24 vs 2/31 
11/65 vs 11/65 
10/60 vs 19/56 
13/47 vs 23/42 
4/34 vs 5/43 
13/60 vs 17/59 
18/99 vs 33/91 
13/68 vs 21/71 











0.125 0. 1.0 2.0 8.0 
Risk Ratio (99% CI) 
Favors PCDT Favors No PCDT 
